Skip to main content
Livermore
Livermore
ZHEN

Deep Track Capital, LP

SEC CIK
0001856083
Latest filing
Aug 14, 2026

Holdings in Q3 2025

Holdings as of Sep 30, 2025, filed Nov 14, 2025. Long positions only; changes compare share counts with Q2 2025.

Institution overview
Positions
56
−9 vs. Q2 2025
Portfolio value
$3.58B
+$472.8M (+15.2%) vs. Q2 2025
Filed
Nov 14, 2025
SEC
Holdings of Deep Track Capital, LP in Q3 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
GHGuardant Health, Inc.COM4,154,086$259.5M7.2%−95,914−2.3%ReducedHistory
IONSIonis Pharmaceuticals IncCOM3,808,144$249.1M7.0%−1,083,400−22.1%ReducedHistory
CYTKCytokinetics IncCOM NEW4,300,000$236.3M6.6%+650,000+17.8%AddedHistory
AKROAkero Therapeutics, Inc.COM4,000,978$190.0M5.3%+958,380+31.5%AddedHistory
APLSApellis Pharmaceuticals, Inc.COM8,000,382$181.0M5.1%+1,000,382+14.3%AddedHistory
TARSTarsus Pharmaceuticals, Inc.COM3,000,000$178.3M5.0%+1,250,000+71.4%AddedHistory
IMVTImmunovant, Inc.COM9,728,845$156.8M4.4%+228,845+2.4%AddedHistory
DVAXDynavax Technologies CorpCOM NEW15,726,349$156.2M4.4%−2,065,137−11.6%ReducedHistory
OCULOcular Therapeutix, IncCOM11,932,137$139.5M3.9%−2,362,283−16.5%ReducedHistory
ETNB89bio, Inc.COM9,356,171$137.5M3.8%−143,829−1.5%ReducedHistory
GPCRStructure Therapeutics Inc.SPONSORED ADS4,215,811$118.0M3.3%−918,106−17.9%ReducedHistory
VRDNViridian Therapeutics, Inc.COM5,380,449$116.1M3.2%00.0%UnchangedHistory
PTGXProtagonist Therapeutics, IncCOM1,715,691$114.0M3.2%−1,530,208−47.1%ReducedHistory
AXSMAxsome Therapeutics, Inc.COM900,000$109.3M3.1%+98,629+12.3%AddedHistory
PCVXVaxcyte, Inc.COM3,000,000$108.1M3.0%+850,000+39.5%AddedHistory
MAZEMaze Therapeutics, Inc.COM3,948,910$102.4M2.9%00.0%UnchangedHistory
IMCRImmunocore Holdings plcADS1,800,000$65.4M1.8%00.0%UnchangedHistory
BBIOBridgeBio Pharma, Inc.COM1,200,000$62.3M1.7%+300,000+33.3%AddedHistory
GERNGeron CorpCOM41,096,522$56.3M1.6%−1,903,478−4.4%ReducedHistory
TERNTerns Pharmaceuticals, Inc.COM7,495,000$56.3M1.6%00.0%UnchangedHistory
NRIXNurix Therapeutics, Inc.COM6,057,024$56.0M1.6%−7,886−0.1%ReducedHistory
MBXMBX Biosciences, Inc.COM3,150,000$55.1M1.5%+961,408+43.9%AddedHistory
EXASExact Sciences CorpCOM1,000,000$54.7M1.5%+1,000,000NewHistory
LBRXLB Pharmaceuticals IncCOM SHS3,352,804$52.9M1.5%+3,352,804NewHistory
CLDXCelldex Therapeutics, Inc.COM NEW2,000,000$51.7M1.4%00.0%UnchangedHistory
ORKAOruka Therapeutics, Inc.COM2,654,781$51.1M1.4%+735,983+38.4%AddedHistory
XENEXenon Pharmaceuticals Inc.COM1,200,000$48.2M1.3%−150,000−11.1%ReducedHistory
CMPSCOMPASS Pathways plcSPONSORED ADS7,859,648$45.0M1.3%−971,359−11.0%ReducedHistory
ANIPAni Pharmaceuticals IncCOM450,000$41.2M1.2%−250,000−35.7%ReducedHistory
BCAXBicara Therapeutics Inc.COM2,426,657$38.3M1.1%00.0%UnchangedHistory
OLMAOlema Pharmaceuticals, Inc.COM3,470,172$34.0M0.9%+27,339+0.8%AddedHistory
CDTXCidara Therapeutics, Inc.COM NEW300,000$28.7M0.8%+50,000+20.0%AddedHistory
QUREuniQure N.V.SHS483,092$28.2M0.8%+483,092NewHistory
DYNDyne Therapeutics, Inc.COM2,000,000$25.3M0.7%+2,000,000NewHistory
JBIOJade Biosciences, Inc.COM NEW2,279,892$19.7M0.5%−229,409−9.1%ReducedHistory
RAPTRAPT Therapeutics, Inc.COM NEW751,422$19.4M0.5%00.0%UnchangedHistory
GHRSGH Research PLCORDINARY SHARES1,250,000$17.9M0.5%−750,000−37.5%ReducedHistory
DFTXDefinium Therapeutics, Inc.Stock1,500,000$17.7M0.5%−1,000,000−40.0%ReducedHistory
ENGNenGene Therapeutics Inc.COM2,239,353$15.3M0.4%−2,318,222−50.9%ReducedHistory
GMABGenmab A/SSPONSORED ADS481,267$14.8M0.4%+481,267NewHistory
TNGXTango Therapeutics, Inc.COM1,454,562$12.2M0.3%+1,454,562NewHistory
CNTXContext Therapeutics Inc.COM7,419,355$7.19M0.2%00.0%UnchangedHistory
IMAImageneBio, Inc.COM878,516$7.16M0.2%+668,890+319.1%AddedConverted for a 1-for-12 splitHistory
XNCRXencor IncCOM549,439$6.44M0.2%00.0%UnchangedHistory
HELPCybin Inc.COM NEW1,000,000$5.89M0.2%−529,987−34.6%ReducedHistory
CRMDCorMedix Inc.COM500,000$5.82M0.2%+500,000NewHistory
PEPGPepGen Inc.COM1,200,000$5.54M0.2%+1,200,000NewHistory
CBIOCrescent Biopharma, Inc.COM453,686$5.39M0.2%00.0%UnchangedHistory
ALGSAligos Therapeutics, Inc.COM NEW444,110$4.35M0.1%00.0%UnchangedHistory
AUTLAutolus Therapeutics plcSPON ADS2,568,613$4.19M0.1%−14,283,534−84.8%ReducedHistory
XFORX4 Pharmaceuticals, IncCOM NEW1,122,484$3.84M0.1%+1,122,484NewHistory
ACADAcadia Pharmaceuticals IncCOM105,085$2.24M0.1%+105,085NewHistory
AVTXAvalo Therapeutics, Inc.COM NEW144,600$1.84M0.1%−422,503−74.5%ReducedHistory
BMRNBiomarin Pharmaceutical IncCOM24,856$1.35M<0.1%+24,856NewHistory
ZURAZura Bio LtdCLASS A ORD SHS259,014$1.12M<0.1%−1,468,548−85.0%ReducedHistory
CLYMClimb Bio, Inc.COM509,789$1.02M<0.1%−530,326−51.0%ReducedHistory

Sold out since Q2 2025 (20)

Positions held at the end of Q2 2025 that are gone from this filing.

Positions of Deep Track Capital, LP sold out since Q2 2025
SecurityClassShares in Q2 2025Value in Q2 2025% of portfolio in Q2 2025History
INSMINSMED IncCOM PAR $.011,750,000$176.1M5.7%History
RAREUltragenyx Pharmaceutical Inc.COM1,350,000$49.1M1.6%History
DNTHDianthus Therapeutics, Inc.COM2,233,148$41.6M1.3%History
MTSRMetsera, Inc.COM1,094,408$31.1M1.0%History
TECXTectonic Therapeutic, Inc.COM1,401,938$27.9M0.9%History
ABVXAbivax S.A.SPONSORED ADS3,480,144$26.6M0.9%History
UPBUpstream Bio, Inc.COM1,442,767$15.8M0.5%History
MRUSMerus N.V.COM275,000$14.5M0.5%History
BCYCBicycle Therapeutics PLCSPONSORED ADS1,203,244$8.36M0.3%History
CNTACentessa Pharmaceuticals plcSPONSORED ADS500,000$6.57M0.2%History
NVAXNovavax IncCOM NEW998,542$6.29M0.2%History
IVVDInvivyd, Inc.COM8,585,980$6.14M0.2%History
PLRXPliant Therapeutics, Inc.COM3,947,807$4.58M0.1%History
SRPTSarepta Therapeutics, Inc.COM259,800$4.44M0.1%History
INOInovio Pharmaceuticals, Inc.COM SHS1,981,370$4.03M0.1%History
KRROKorro Bio, Inc.COM277,966$3.47M0.1%History
SYRESpyre Therapeutics, Inc.COM NEW219,015$3.28M0.1%History
SEPNSepterna, Inc.COM121,716$1.29M<0.1%History
RAPPRapport Therapeutics, Inc.COM98,237$1.12M<0.1%History
OKUROnKure Therapeutics, Inc.COM CL A180,510$431.4K<0.1%History